Alx oncology appoints allison dillon as chief business officer

South san francisco, calif., may 07, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced the appointment of allison dillon, ph.d., as chief business officer (“cbo”).
ALXO Ratings Summary
ALXO Quant Ranking